Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer

Recent preclinical studies revealed the efficacy of combined use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib in breast and prostate cancers. The current study investigated the effect of such drug combination on ovarian cancer. Here we showed that combined inhibition of PI3K and PARP effecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Dong, Wang, Min, Jiang, Nan, Zhang, Yuan, Bian, Xing, Wang, Xiaoqing, Roberts, Thomas M., Zhao, Jean J., Liu, Pixu, Cheng, Hailing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914348/
https://www.ncbi.nlm.nih.gov/pubmed/26909613
http://dx.doi.org/10.18632/oncotarget.7549

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914348/
https://www.ncbi.nlm.nih.gov/pubmed/26909613
http://dx.doi.org/10.18632/oncotarget.7549

Ejemplares similares